Proteomika. Biomarcadores para el diagnóstico no invasivo de enfermedades complejas.

Traditionally two-dimensional electrophoresis (2DE) has been the technology of choice for the identification of differentially expressed proteins with potential as diagnostic markers for diseases such as cancer. Proteomika actively works on the implementation of new and complementary techniques, such as NAPPA, in order to identify and validate biomarkers as well as methods based on quantitative mass spectrometry.

Differential proteomics using 2DE entails a generation of proteome “maps” derived from samples obtained from numerous individuals representing each of the populations in the study (e.g. healthy/diseased). Subsequently, these proteome maps are digitized and compared using specialized software for analysis of 2DE gel images that employs powerful algorithms for the detection, quantification and matching, of spots allowing proteomic signatures that distinguish the populations under study to be differentiated.

Proteomika has undertaken numerous biomarker identification programs across a range of different human diseases through the differential proteomic analysis of thousands of biological samples in order to identify novel protein biomarkers whose pattern of expression is significantly altered between the population groups under study.

2DE, like other “’omics” technologies, provides a powerful screening tool that generates large quantities of information that must be filtered and evaluated with adequate statistical tools before data can be interpreted. Proteomika has a highly experienced bioinformatics team that is responsible for data analysis and the generation of multivariate models for disease diagnosis based on biomarker detection.